• Algorae and Peter Mac's VCFG to validate AI-predicted drug combinations
• 24 high-priority drug candidates to be screened across 4 cancer cell lines
• Collaboration aims to accelerate pipeline development and support regulatory/commercial pathways

Algorae Pharmaceuticals has entered into an agreement with the Victorian Centre for Functional Genomics (VCFG) at Peter MacCallum Cancer Centre for a second program to independently validate the predictions from AlgoraeOS version 2 (AOS2). Following analysis of the initial AOS2 prediction set, 24 high-priority drug combination candidates have been selected for preclinical validation. Under the agreement, VCFG will perform compound synergy interaction screens using its high-throughput technologies and synergy assessment methodologies. The collaboration is designed to evaluate the predicted synergy of drug combinations across four distinct cancer cell lines: glioblastoma, rhabdomyosarcoma, melanoma and chronic myelogenous leukaemia. Successful validation of these AI-predicted drug combinations could significantly de-risk their further development and support internal advancement, out-licensing or partnership opportunities, as well as expansion of the AI-driven discovery pipeline into additional therapeutic areas.

This second agreement with Peter Mac marks another significant milestone for Algorae. AlgoraeOS v2 represents a major advancement in the company's AI prediction capabilities, and the validation program is expected to generate key preclinical data within six months, accelerating the company's pipeline development.